Shigella 4V

PreclinicalBiologic

LLimmaTech Biologics AG

Shigella 4V is one of 12 biologic programs targeting Shigellosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ShigellosisCompleted

ShigellosisPreclinical

Completed

Competition

Competitive Landscape

16 competitors in Shigellosis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 4

Bacteriophage

AAdaptive Phage Therapeutics, Inc.

Phase 2

1 5

MR-Vac

GSK

Phase 2

1 6

TYPHIBEV

GSK

Phase 2

1 7

Gsk's Investigational Vaccine 692342

GSK

Phase 1

—8

Ceftriaxon

IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group

Phase 2

1 9

Altsonflex1-2-3

GSK

Phase 1

1 10

Menacwy

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Shigellosis1 trial

Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants

Completed·LLimmaTech Biologics AG·Preclinical·NCT04056117·597 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Shigella 4V. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Shigella 4V compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Shigella 4V. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LimmaTech Biologics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: LLimmaTech Biologics AG

Shigella 4V

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Shigellosis1 trial

References

Drug Info

Quick Facts

Related News